Updated on 11 September 2013
Mayne Pharma has granted HPPI exclusive rights to SUBA-Itraconazole for the treatment of cancer in the US, and Mayne Pharma retains rights outside the US, and also obtains an exclusive license from HPPI to utilize all current and any future development intellectual property generated by HPPI.
Mayne Pharma CEO Mr Scott Richards said in the press statement, "We are very excited to announce our collaboration with HPPI which we believe is the best commercial vehicle for the development and exploitation of SUBA-Itraconazole as a potential treatment for certain cancers. HPPI has an experienced management team who are passionate about the potential of SUBA-Itraconazole in treating cancer. HPPI also brings relevant intellectual property to supplement that of our existing SUBA technology patent."
He also added, "Over the last 18 months, the team behind HPPI has explored the clinical potential of itraconazole as a treatment for cancer which culminated in a restructure of HPPI into a public company which has commenced trading on the OTCPink market. HPPI will be seeking market funding for the clinical development and regulatory program. We look forward to a productive partnership with HPPI as we work closely together to progress SUBA- Itraconazole through the development process."
He also said that since itraconazole is already an FDA approved drug, the company believes that the potential exists for an expedited development program due to the drug's well established safety profile. "We are further encouraged by the recently reported third party phase II data demonstrating itraconazole's anti-cancer effects in humans," he added.